5 Key Takeaways

• 1

  Empagliflozin, an SGLT2 inhibitor, was studied for its impact on diabetic retinopathy in type 2 diabetes patients.

• 2

  The study compared empagliflozin with DPP4 inhibitors using insurance claims data from two US insurers and Medicare.

• 3

  There was no significant difference in the risk of nonproliferative diabetic retinopathy between empagliflozin and DPP4 inhibitors.

• 4

  Empagliflozin was associated with a 22% reduced risk of progression to advanced diabetic retinopathy in patients with preexisting NPDR.

• 5

  The researchers suggested that empagliflozin's protective effect may relate to SGLT2 receptor inhibition or differential hemoglobin A1c reduction.